ZBIOZenas BioPharma (USA), LLCSigning up patients
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 990 (planned)
- Started
- Mar 23, 2026
- Main results expected
- Jun 2030
- Fully finished
- Jul 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Measured over: Up to approximately 120 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07299019 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC